ImmunoGen Inc (IMGN)

[skitahoe]

I believe a week from tomorrow we'll learn more about the trials, and their interpretation of them when they hold their quarterly webcast. Unfortunately, it's at 5 a.m. here on the West Coast, so I'll not be listening in live, but should know how good, or bad, it was in looking at the stock price that day. I do intend to listen to what's said later.

I believe that like other things IMGN or it's clinicians have presented in the past, the presentation wasn't as positive as I believe the people developing it are. They are reporting the facts to date in the trial, but cannot comment on observations in people who haven't been in the trial long enough to be evaluated over the required amount of time. In short, I believe the trial will improve as its duration reaches its conclusion. Certainly it may not meet what was seen in the first 18 patients who were treated, but benefits are being seen now, and they will be better as more data comes in.

What will be far more important is the Phase 3 Trial which may be preliminarily concluded within a month. I'm uncertain if top line data can be discussed after preliminary conclusion, or only after final conclusion early next year, but I believe it will give investors reason to believe an FDA approval for the drug as a monotherapy will be in the cards. I do believe it can do better in combination with others, but as a monotherapy it will exceed the SOC.

Gary